Pharma Focus Asia

Rheos Medicines Announces Worldwide Collaboration with Roche to Discover and Develop Novel Medicines in the Field of Immunometabolism

Friday, December 20, 2019

Rheos Medicines (Rheos), a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe autoimmune disorders, inflammatory diseases and cancer, today announced that it has entered into a worldwide exclusive collaboration, option and license agreement with Roche to discover, develop and commercialize novel therapeutics in the field of immunometabolism.

“We are thrilled to be leveraging our expertise in human immune cell metabolism in partnership with Roche,” said Barbara Fox, Chief Executive Officer of Rheos. “We believe that our team’s deep experience in immunology and cellular metabolism along with our unique approach have the potential to unlock a new frontier in precision medicine for immune mediated disease. This partnership will help to accelerate the translation of insights in immunometabolism to the development of groundbreaking therapeutics for patients with autoimmune and inflammatory diseases.”

"We are excited to partner with Rheos and look forward to the development of a novel class of therapeutics for patients with autoimmune and inflammatory disease,” said Gijs van den Brink, SVP and Global Head of Immunology, Infectious Diseases and Ophthalmology at Roche Pharma Early Research and Development. "We believe Rheos' proprietary platform and expertise in immunometabolism is a strong complement to Roche's expertise in autoimmunity and inflammation and in developing and commercializing innovative therapies."

Under the terms of the agreement, Rheos will conduct an exclusive research effort to identify novel targets in immunometabolism that modify the fate or function of certain human immune cells. In addition, Rheos will also be responsible for drug discovery efforts under the collaboration. Roche will receive an option to exclusively license a defined number of programs emerging from the collaboration. For certain products within the collaboration, Rheos and Roche could share worldwide development and US commercial rights.

Rheos will receive an upfront cash payment of $42.5 million upon execution and will be eligible to receive up to approximately $90 million for specified research and preclinical development milestones as well as option fees. Rheos will also be eligible to receive up to an additional approximately $660 million in specified development, regulatory and sales related milestones across the programs and tiered royalties on net sales. For those products for which Rheos and Roche could share development and commercial rights Rheos will be entitled to additional financial compensation within the US and ex- US commensurate with the share of its financial investment in development and commercialization.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024